约70%的上皮性卵巢癌患者确诊时已属晚期。当无法进行初次最佳手术时，新辅助化疗后进行中间减瘤手术是其中一种治疗选择。然而，对于手术的最佳时机并无共识。CA125是卵巢癌中众所周知的肿瘤标志物。

适应症：Ovarian Cancer、Fallopian Tube Cancer、Primary Peritoneal Carcinoma

入组条件

Patients aged 18 years old or older
Patients with Eastern Cooperative Oncology Group score 0-1 within 28 days prior to recruitment
Patients who can sign the informed consent
Patients with stage III-IV histologically or cytologically confirmed epithelial ovarian cancer (EOC), fallopian tube or primary peritoneal cancer not amenable for PDS
Patients who have baseline computed tomography (CT) of thorax, abdomen and pelvis.
Patients who are planned for neoadjuvant chemotherapy (NACT) using 3-weekly carboplatin and paclitaxel. Those who have received one cycle of NACT may be eligible if the CA125 schedule of the study group can be matched.
Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal)
Patients who agree for chemotherapy and interval debulking surgery (IDS) if the disease becomes operable after NACT
Patients with adequate hematologic, liver and renal functions for chemotherapy
Patients who agree to receive adjuvant chemotherapy after IDS. The total number of NACT and adjuvant chemotherapy should be four or above, up to maximum of 9 cycles.
Patients who have childbearing potential should practice highly effective contraception throughout the study until at least 30 days after completion of the treatment.
Patients must have either germline and / or somatic BRCA test, or homologous recombination deficiency (HRD) test.

Patients who have borderline malignancy, or non-EOC like germ cell or sex cord tumor, or metastatic diseases from other origins
Patients with mucinous and neuroendocrine histology
Patients with history of other malignancies within five years
Patients who are eligible for primary debulking surgery (PDS)
Patients who cannot undergo PDS because of parametrial and/or vaginal involvement alone
Patients who are not fit for PDS because of medical morbidities or refusal of operation
Patients who have already started NACT outside the study centers, except those who have received only one cycle within 7 days and the baseline CA125 value within 3 days of NACT (normal cut-off 35 U/ml) is available
Patients who participate in other interventional studies
Patients who are pregnant or breastfeeding
Patients who have contraindications to platinum-based chemotherapy
Patents with active tuberculosis, history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) are excluded.

入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。

晚期卵巢癌中间减瘤手术的个人化时机